50 Best Peptides

This website is for informational purposes only and does not constitute medical advice. Read disclaimer

#127

Gastrin

GastrointestinalGastrin-17Gastrin-34Big GastrinLittle GastrinPentagastrin

A peptide hormone produced by G-cells of the stomach that stimulates gastric acid secretion, with important roles in gastrointestinal physiology and as a diagnostic marker for gastric disorders.

Share:

Overview

Gastrin is a peptide hormone primarily produced by G-cells in the antral region of the stomach and the proximal duodenum. First isolated by Roderic Gregory and Hilda Tracy in 1964, gastrin exists in multiple molecular forms, with gastrin-17 (G-17, "little gastrin") and gastrin-34 (G-34, "big gastrin") being the most physiologically significant. Both forms share an identical C-terminal tetrapeptide amide sequence that is essential for biological activity.

Gastrin is the primary hormonal stimulator of gastric acid secretion. It is released in response to stomach distension, vagal stimulation, and the presence of amino acids and peptides in the gastric lumen. Gastrin acts on CCK-2 receptors (also called gastrin receptors) on enterochromaffin-like (ECL) cells of the gastric mucosa, stimulating them to release histamine. Histamine then acts on parietal cell H2 receptors to stimulate hydrochloric acid secretion. Gastrin also has direct effects on parietal cells and stimulates the growth of the gastric mucosa (trophic effect).

In clinical medicine, serum gastrin levels serve as an important diagnostic marker. Elevated fasting gastrin levels can indicate Zollinger-Ellison syndrome (gastrinoma), atrophic gastritis, pernicious anemia, or chronic use of proton pump inhibitors (PPIs). The secretin stimulation test, in which IV secretin paradoxically increases gastrin levels in gastrinoma patients while decreasing or maintaining levels in other hypergastrinemia causes, is a key diagnostic tool.

Pentagastrin, a synthetic analog containing the C-terminal tetrapeptide of gastrin, was historically used as a diagnostic agent to assess maximal acid output. Gastrin also has relevance in cancer biology: the trophic effects of chronic hypergastrinemia have been implicated in the development of gastric carcinoid tumors from ECL cells, a known consequence of long-term PPI use in some patients.

Research Uses & Applications

  • Diagnostic biomarker for Zollinger-Ellison syndrome (gastrinoma) and other hypergastrinemia causes
  • Secretin stimulation test for differential diagnosis of hypergastrinemia
  • Research into gastric acid regulation and gastrointestinal physiology
  • Monitoring of gastrin levels during long-term PPI therapy
  • Studied for trophic effects on gastrointestinal mucosa and potential role in carcinogenesis
  • Pentagastrin historically used for gastric acid secretion testing

Key Research Findings

  • Clinical studies established serum gastrin measurement as essential in the diagnosis of Zollinger-Ellison syndrome, with levels typically exceeding 1000 pg/mL in gastrinoma.
  • Long-term PPI studies showed chronic acid suppression leads to reactive hypergastrinemia and ECL cell hyperplasia, with rare progression to gastric carcinoid tumors.
  • The secretin stimulation test showed sensitivity of approximately 85-90% and specificity above 95% for diagnosing gastrinoma.
  • Research on Helicobacter pylori infection revealed that the bacterium stimulates gastrin release from G-cells, contributing to increased acid secretion in duodenal ulcer disease.
  • Preclinical studies demonstrated gastrin promotes colorectal cancer cell growth through CCK-2 receptor-mediated signaling, suggesting a potential role as a therapeutic target.

Risks & Side Effects

  • Exogenous gastrin administration causes gastric acid hypersecretion and can exacerbate peptic ulcer disease.
  • Chronic hypergastrinemia is associated with ECL cell hyperplasia and increased risk of gastric carcinoid tumors.
  • Pentagastrin can cause nausea, flushing, and abdominal discomfort when administered diagnostically.
  • Elevated gastrin from any cause may promote mucosal growth with potential neoplastic implications.
  • Not used as a therapeutic agent; clinical interest lies in measuring and modulating gastrin levels.

Administration

Gastrin is measured in serum as a diagnostic biomarker (normal fasting levels: < 100 pg/mL). Pentagastrin (when available) was administered subcutaneously at 6 mcg/kg for gastric acid secretion testing. Secretin stimulation test involves IV secretin (0.4 mcg/kg) with serial gastrin measurements. Gastrin itself is not administered therapeutically.

Legal Status

Serum gastrin assays are standard clinical laboratory tests available worldwide. Pentagastrin is no longer commercially available in many countries, including the United States. Gastrin peptides are available as research reagents. Not a controlled substance.

Frequently Asked Questions

What is Gastrin?

A peptide hormone produced by G-cells of the stomach that stimulates gastric acid secretion, with important roles in gastrointestinal physiology and as a diagnostic marker for gastric disorders.

What are the main uses of Gastrin?

The primary research applications of Gastrin include: Diagnostic biomarker for Zollinger-Ellison syndrome (gastrinoma) and other hypergastrinemia causes; Secretin stimulation test for differential diagnosis of hypergastrinemia; Research into gastric acid regulation and gastrointestinal physiology; Monitoring of gastrin levels during long-term PPI therapy; Studied for trophic effects on gastrointestinal mucosa and potential role in carcinogenesis; Pentagastrin historically used for gastric acid secretion testing.

What are the risks and side effects of Gastrin?

Documented risks and side effects include: Exogenous gastrin administration causes gastric acid hypersecretion and can exacerbate peptic ulcer disease.; Chronic hypergastrinemia is associated with ECL cell hyperplasia and increased risk of gastric carcinoid tumors.; Pentagastrin can cause nausea, flushing, and abdominal discomfort when administered diagnostically.; Elevated gastrin from any cause may promote mucosal growth with potential neoplastic implications.; Not used as a therapeutic agent; clinical interest lies in measuring and modulating gastrin levels.. Always consult a healthcare professional before considering any peptide.

Is Gastrin legal?

Serum gastrin assays are standard clinical laboratory tests available worldwide. Pentagastrin is no longer commercially available in many countries, including the United States. Gastrin peptides are available as research reagents. Not a controlled substance.

How is Gastrin administered?

Gastrin is measured in serum as a diagnostic biomarker (normal fasting levels: < 100 pg/mL). Pentagastrin (when available) was administered subcutaneously at 6 mcg/kg for gastric acid secretion testing. Secretin stimulation test involves IV secretin (0.4 mcg/kg) with serial gastrin measurements. Gastrin itself is not administered therapeutically.

Related Peptides

#112

Linaclotide

Gastrointestinal

#113

Plecanatide

Gastrointestinal

#126

Cholecystokinin (CCK)

Gastrointestinal

#128

Motilin

Gastrointestinal

Stay Updated on Peptide Research

Get the latest peptide research news and updates delivered to your inbox.

Official Store

Experience Peptides on Your Skin

Shop our curated collection of peptide-infused skincare — Copper Peptide serums, anti-aging treatments, hydrogel patches, and more.

Shop Peptide Skincare

Important Disclaimer

The information on this page is for educational and informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement. 50 Best Limited does not endorse, recommend, or promote the use of any peptide for self-administration. Read our full disclaimer.

← #126 Cholecystokinin (CCK)#128 Motilin →